Barclays began coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a report released on Tuesday morning, 24/7 WallStreet reports. The firm issued an overweight rating and a $19.00 target price on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently commented on AMAG. BidaskClub upgraded AMAG Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, May 15th. Zacks Investment Research cut AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 20th. ValuEngine cut AMAG Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, May 28th. SunTrust Banks initiated coverage on AMAG Pharmaceuticals in a research report on Tuesday, March 19th. They issued a hold rating on the stock. Finally, Cantor Fitzgerald restated a hold rating and issued a $14.00 price target (down previously from $17.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, March 14th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $18.78.

AMAG stock opened at $9.52 on Tuesday. The company has a current ratio of 2.30, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The firm has a market cap of $327.20 million, a price-to-earnings ratio of -2.45 and a beta of 0.48. AMAG Pharmaceuticals has a fifty-two week low of $9.15 and a fifty-two week high of $26.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.77). The firm had revenue of $75.80 million for the quarter, compared to the consensus estimate of $90.13 million. AMAG Pharmaceuticals had a negative return on equity of 26.33% and a negative net margin of 30.90%. The firm’s quarterly revenue was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.59) EPS. As a group, equities analysts expect that AMAG Pharmaceuticals will post -5.72 EPS for the current fiscal year.

In other AMAG Pharmaceuticals news, insider Elizabeth Scott Bolgiano acquired 5,000 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, May 9th. The shares were acquired at an average cost of $10.93 per share, with a total value of $54,650.00. Following the completion of the purchase, the insider now directly owns 74,847 shares of the company’s stock, valued at approximately $818,077.71. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Julie Krop acquired 10,000 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Tuesday, May 28th. The stock was acquired at an average cost of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the purchase, the insider now directly owns 81,399 shares of the company’s stock, valued at $806,664.09. The disclosure for this purchase can be found here. Insiders purchased 25,000 shares of company stock worth $260,750 in the last 90 days. 4.90% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. California Public Employees Retirement System boosted its stake in AMAG Pharmaceuticals by 0.8% in the fourth quarter. California Public Employees Retirement System now owns 86,987 shares of the specialty pharmaceutical company’s stock valued at $1,321,000 after buying an additional 690 shares in the last quarter. Texas Permanent School Fund boosted its stake in AMAG Pharmaceuticals by 4.2% in the fourth quarter. Texas Permanent School Fund now owns 22,600 shares of the specialty pharmaceutical company’s stock valued at $343,000 after buying an additional 909 shares in the last quarter. NumerixS Investment Technologies Inc boosted its stake in AMAG Pharmaceuticals by 17.8% in the first quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 1,083 shares in the last quarter. Rhumbline Advisers boosted its stake in AMAG Pharmaceuticals by 1.1% in the first quarter. Rhumbline Advisers now owns 103,866 shares of the specialty pharmaceutical company’s stock valued at $1,338,000 after buying an additional 1,125 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in AMAG Pharmaceuticals by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 285,332 shares of the specialty pharmaceutical company’s stock valued at $4,334,000 after buying an additional 1,613 shares in the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Recommended Story: What is the Coverage Ratio?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.